X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SUN PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SUN PHARMA PANACEA BIOTECH/
SUN PHARMA
 
P/E (TTM) x 81.4 15.0 542.3% View Chart
P/BV x 1.8 3.5 51.2% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 PANACEA BIOTECH   SUN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
SUN PHARMA
Mar-16
PANACEA BIOTECH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1491,201 12.4%   
Low Rs82706 11.7%   
Sales per share (Unadj.) Rs84.1117.5 71.6%  
Earnings per share (Unadj.) Rs-18.319.6 -93.4%  
Cash flow per share (Unadj.) Rs-6.723.8 -28.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs83.7130.5 64.1%  
Shares outstanding (eoy) m61.252,406.60 2.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.48.1 16.9%   
Avg P/E ratio x-6.348.7 -13.0%  
P/CF ratio (eoy) x-17.240.1 -43.0%  
Price / Book Value ratio x1.47.3 18.9%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m7,0742,294,813 0.3%   
No. of employees `0002.814.7 18.6%   
Total wages/salary Rs m1,44947,971 3.0%   
Avg. sales/employee Rs Th1,874.119,169.8 9.8%   
Avg. wages/employee Rs Th527.03,253.0 16.2%   
Avg. net profit/employee Rs Th-407.73,197.9 -12.8%   
INCOME DATA
Net Sales Rs m5,154282,697 1.8%  
Other income Rs m1006,170 1.6%   
Total revenues Rs m5,254288,867 1.8%   
Gross profit Rs m-76683,239 -0.9%  
Depreciation Rs m71110,135 7.0%   
Interest Rs m1,5034,769 31.5%   
Profit before tax Rs m-2,88174,505 -3.9%   
Minority Interest Rs m11-11,126 -0.1%   
Prior Period Items Rs m-6-19 30.5%   
Extraordinary Inc (Exp) Rs m1,771-6,852 -25.8%   
Tax Rs m179,349 0.2%   
Profit after tax Rs m-1,12147,159 -2.4%  
Gross profit margin %-14.929.4 -50.5%  
Effective tax rate %-0.612.5 -4.6%   
Net profit margin %-21.816.7 -130.4%  
BALANCE SHEET DATA
Current assets Rs m3,810308,646 1.2%   
Current liabilities Rs m8,365132,477 6.3%   
Net working cap to sales %-88.462.3 -141.8%  
Current ratio x0.52.3 19.5%  
Inventory Days Days15683 187.7%  
Debtors Days Days6788 76.6%  
Net fixed assets Rs m14,480133,606 10.8%   
Share capital Rs m612,407 2.5%   
"Free" reserves Rs m903266,909 0.3%   
Net worth Rs m5,127314,042 1.6%   
Long term debt Rs m5,83231,167 18.7%   
Total assets Rs m19,433542,196 3.6%  
Interest coverage x-0.916.6 -5.5%   
Debt to equity ratio x1.10.1 1,146.1%  
Sales to assets ratio x0.30.5 50.9%   
Return on assets %2.09.6 20.5%  
Return on equity %-21.915.0 -145.6%  
Return on capital %3.617.8 20.5%  
Exports to sales %24.514.0 175.2%   
Imports to sales %10.23.1 324.1%   
Exports (fob) Rs m1,26439,572 3.2%   
Imports (cif) Rs m5258,882 5.9%   
Fx inflow Rs m1,53942,171 3.6%   
Fx outflow Rs m94221,583 4.4%   
Net fx Rs m59720,588 2.9%   
CASH FLOW
From Operations Rs m59967,694 0.9%  
From Investments Rs m-438-44,549 1.0%  
From Financial Activity Rs m-303-19,243 1.6%  
Net Cashflow Rs m-1413,902 -3.6%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 5.1 11.7%  
FIIs % 1.3 23.0 5.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 8.3 284.3%  
Shareholders   10,259 133,026 7.7%  
Pledged promoter(s) holding % 35.1 0.5 6,617.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   GLENMARK PHARMA  SANOFI INDIA  ALEMBIC PHARMA  DR. REDDYS LAB  NOVARTIS  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 21, 2017 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS